177 related articles for article (PubMed ID: 26518542)
1. Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors.
Morfouace M; Nimmervoll B; Boulos N; Patel YT; Shelat A; Freeman BB; Robinson GW; Wright K; Gajjar A; Stewart CF; Gilbertson RJ; Roussel MF
J Neurooncol; 2016 Jan; 126(2):225-34. PubMed ID: 26518542
[TBL] [Abstract][Full Text] [Related]
2. Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.
Holleran JL; Beumer JH; McCormick DL; Johnson WD; Newman EM; Doroshow JH; Kummar S; Covey JM; Davis M; Eiseman JL
Cancer Chemother Pharmacol; 2015 Oct; 76(4):803-11. PubMed ID: 26321472
[TBL] [Abstract][Full Text] [Related]
3. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
Beumer JH; Parise RA; Newman EM; Doroshow JH; Synold TW; Lenz HJ; Egorin MJ
Cancer Chemother Pharmacol; 2008 Jul; 62(2):363-8. PubMed ID: 17899082
[TBL] [Abstract][Full Text] [Related]
4. Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors.
Coyne GO'; Wang L; Zlott J; Juwara L; Covey JM; Beumer JH; Cristea MC; Newman EM; Koehler S; Nieva JJ; Garcia AA; Gandara DR; Miller B; Khin S; Miller SB; Steinberg SM; Rubinstein L; Parchment RE; Kinders RJ; Piekarz RL; Kummar S; Chen AP; Doroshow JH
Cancer Chemother Pharmacol; 2020 May; 85(5):979-993. PubMed ID: 32314030
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution, Tumor Detection, and Radiation Dosimetry of
Young CR; Adler S; Eary JF; Lindenberg ML; Jacobs PM; Collins J; Kummar S; Kurdziel KA; Choyke PL; Mena E
J Nucl Med; 2019 Apr; 60(4):492-496. PubMed ID: 30389817
[TBL] [Abstract][Full Text] [Related]
6. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.
Newman EM; Morgan RJ; Kummar S; Beumer JH; Blanchard MS; Ruel C; El-Khoueiry AB; Carroll MI; Hou JM; Li C; Lenz HJ; Eiseman JL; Doroshow JH
Cancer Chemother Pharmacol; 2015 Mar; 75(3):537-46. PubMed ID: 25567350
[TBL] [Abstract][Full Text] [Related]
7. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Perez LM; Greer S
Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Holleran JL; Covey JM; Egorin MJ
Clin Cancer Res; 2006 Dec; 12(24):7483-91. PubMed ID: 17138702
[TBL] [Abstract][Full Text] [Related]
9. Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2344-53. PubMed ID: 2436761
[TBL] [Abstract][Full Text] [Related]
10. Stability of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in combination.
Guo D; Myrdal PB; Karlage KL; O'Connell SP; Wissinger TJ; Tabibi SE; Yalkowsky SH
AAPS PharmSciTech; 2010 Mar; 11(1):247-52. PubMed ID: 20151336
[TBL] [Abstract][Full Text] [Related]
11. Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2354-62. PubMed ID: 2952263
[TBL] [Abstract][Full Text] [Related]
12. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Covey JM; Egorin MJ
Clin Cancer Res; 2008 Jun; 14(11):3529-35. PubMed ID: 18519786
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 5-[
Yu HM; Chiu CH; Chen WT; Wu CH; Lin PY; Huang YY; Chen JH; Tzen KY; Shiue CY; Lin WJ
Appl Radiat Isot; 2019 Jun; 148():152-159. PubMed ID: 30959352
[TBL] [Abstract][Full Text] [Related]
14. Establishing a Preclinical Multidisciplinary Board for Brain Tumors.
Nimmervoll BV; Boulos N; Bianski B; Dapper J; DeCuypere M; Shelat A; Terranova S; Terhune HE; Gajjar A; Patel YT; Freeman BB; Onar-Thomas A; Stewart CF; Roussel MF; Guy RK; Merchant TE; Calabrese C; Wright KD; Gilbertson RJ
Clin Cancer Res; 2018 Apr; 24(7):1654-1666. PubMed ID: 29301833
[No Abstract] [Full Text] [Related]
15. Five-chlorodeoxycytidine, a tumor-selective enzyme-driven radiosensitizer, effectively controls five advanced human tumors in nude mice.
Greer S; Alvarez M; Mas M; Wozniak C; Arnold D; Knapinska A; Norris C; Burk R; Aller A; Dauphinée M
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):791-806. PubMed ID: 11697326
[TBL] [Abstract][Full Text] [Related]
16. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
Beumer JH; Eiseman JL; Gilbert JA; Holleran JL; Yellow-Duke AE; Clausen DM; D'Argenio DZ; Ames MM; Hershberger PA; Parise RA; Bai L; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2011 Feb; 67(2):421-30. PubMed ID: 20443002
[TBL] [Abstract][Full Text] [Related]
17. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Greer SB
Cancer Res; 1985 Nov; 45(11 Pt 1):5270-80. PubMed ID: 2932216
[TBL] [Abstract][Full Text] [Related]
18. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
Funamizu N; Lacy CR; Fujita K; Furukawa K; Misawa T; Yanaga K; Manome Y
PLoS One; 2012; 7(5):e37424. PubMed ID: 22616006
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and mechanism of action of 5-fluorodeoxycytidine.
Newman EM; Santi DV
Proc Natl Acad Sci U S A; 1982 Nov; 79(21):6419-23. PubMed ID: 6959127
[TBL] [Abstract][Full Text] [Related]
20. 5-Iododeoxyuridine increases the efficacy of the radioimmunotherapy of human tumors growing in nude mice.
Santos O; Pant KD; Blank EW; Ceriani RL
J Nucl Med; 1992 Aug; 33(8):1530-4. PubMed ID: 1634946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]